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Abstract
Near-infrared photoimmunotherapy (NIR PIT) employs the photoabsorbing dye IR700 conjugated 
to antibodies specific for cell surface epidermal growth factor receptor (EGFR). NIR PIT has 
shown highly selective cytotoxicity in vitro and in vivo. Cell necrosis is thought to be the main 
mode of cytotoxicity based mainly on in vitro studies. To better understand the acute effects of 
NIR PIT, molecular imaging studies were performed to assess its cellular and vascular effects.
In addition to in vitro studies for cytotoxicity of NIR PIT, the in vivo tumoricidal effects and 
hemodynamic changes induced by NIR PIT were evaluated by 13C MRI using hyperpolarized 
[1,4-13C2] fumarate, R2* mapping from T2*-weighted MRI, and photoacoustic imaging. In vitro 
studies confirmed that NIR PIT resulted in rapid cell death via membrane damage, with evidence 
for rapid cell expansion followed by membrane rupture. Following NIR PIT, metabolic MRI using 
hyperpolarized fumarate showed the production of malate in EGFR-expressing A431 tumor 
xenografts, providing direct evidence for photosensitized tumor necrosis induced by NIR PIT. R2* 
mapping studies showed temporal changes in oxygenation, with an accompanying increase of 
deoxyhemoglobin at the start of light exposure followed by a sustained decrease after cessation of 
light exposure. This result suggests a rapid decrease of blood flow in EGFR-expressing A431 
tumor xenografts, which is supported by the results of the photoacoustic imaging experiments. Our 
Address correspondence to: Murali K. Cherukuri, Ph.D., Radiation Biology Branch, National Cancer Institute, Bldg. 10, Room B3-
B69, Bethesda, MD 20892, Phone: (301) 451-6752, Fax: (301) 480-2238, cherukum@mail.nih.gov. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest: No potential conflicts of interest were disclosed.
HHS Public Access
Author manuscript
Free Radic Biol Med. Author manuscript; available in PMC 2019 February 20.
Published in final edited form as:
Free Radic Biol Med. 2018 February 20; 116: 1–10. doi:10.1016/j.freeradbiomed.2017.12.034.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
findings suggest NIR PIT mediates necrosis and hemodynamic changes in tumors by 
photosensitized oxidation pathways and that these imaging modalities, once translated, may be 
useful in monitoring clinical treatment response.
graphical abstract
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Introduction
Photodynamic therapy (PDT) is a well-known cancer treatment modality in which a visible 
light-absorbing chromophore or photosensitizer (PS) is administered intravenously followed 
by selective irradiation of the tumor with visible light [1]. The PS accumulates preferentially 
in the tumor via the enhanced permeability and retention (EPR) effect.
The clinical application of PDT is limited for several reasons. Selective illumination of the 
tumor not only results in tumor killing but can also cause damage to adjacent normal tissue 
[1–3]. In addition, the patient remains light-sensitive after exposure to the PS. Finally, the 
photochemical mechanisms underlying PDT are thought to be mediated by free radicals and 
singlet oxygen.
PSg
1 PSe
1 (1)
PSe
1 PSe
3 (2)
PSe
3 + O2
3 PS + O2
1 (Type II) (3)(Energy transfer)
or  PSe
3 + LH L· + PS · −(Type I) (4)(Electron transfer)
Where PSg and PSe are ground state and excited state of photosensitizer, respectively. 1PSg 
is excited to 1PSe by irradiating light (1), which then transits to 3PSe via intersystem 
crossing (2). Energy transfer results in generation of singlet oxygen in type II reaction (3), 
whereas electron transfer results in generation of free radical in type I reaction (4). Free 
radicals generated through Type I photochemical mechanisms by the PS can lead to 
membrane lipid peroxidation, while singlet oxygen generated by a Type II mechanism adds 
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across double bonds of membrane lipids [5–7]. Oxidative stress supported by Type I and 
Type II mechanisms cause membrane damage [6]. Thus, while PDT is used in selected 
cases, it is still not widely applicable in cancer treatment [1, 4].
In contrast to PDT, which uses a non-targeted PS, in near-infrared photoimmunotherapy 
(NIR PIT), PSs are covalently linked to an antibody to provide tumor selectivity [8, 9]. The 
highly hydrophilic PS, IR700, when conjugated to an antibody targeting cell membrane 
receptors expressed in tumors, can accumulate selectively at doses able to induce phototoxic 
effects [8–10]. For example, using an anti-epidermal growth factor receptor (EGFR) 
monoclonal antibody (mAb) conjugated to IR700, NIR PIT demonstrated potent and 
selective cytotoxic effects immediately after light exposure in tumor xenografts and in 
spontaneous EGFR-expressing cancer, resulting in dramatic reductions in tumor size [11–
13]. In vitro, cells exhibited rapid swelling and membrane rupture, indicating a necrotic 
mechanism. Systematic studies showed that: a) tumor killing was dependent on IR700-Ab 
dose and light exposure; b) in targeting the EGFR receptor, panitumumab was superior to 
cetuximab; c) multiple NIR PIT cycles proved superior to a single treatment; and d) 
antibody fragments were as efficacious as whole antibodies [14–17].
NIR PIT studies also showed a nearly immediate increase in vascular permeability that 
facilitated the delivery of intravenous therapeutics, such as liposomal encapsulated 
doxorubicin, resulting in a synergy between NIR PIT and chemotherapy [18–20]. More 
recent studies have shown that NIR PIT can be used to target the immunosuppressive Treg 
cells which help cancer cells evade the normal immune response. This not only causes 
regression in treated tumors but also leads to responses in untreated tumors, opening avenues 
for incorporating this modality in cancer immunotherapy [21, 22].
Several imaging techniques have been used to monitor the effects of NIR PIT. 
Bioluminescence imaging and fluorescence lifetime imaging have been used to follow 
treatment responses preclinically [23, 24]. Clinically translatable imaging techniques include 
positron emission tomography (PET) with 18F-fludeoxyglucose ([18F]FDG) uptake, 
magnetic resonance imaging (MRI) measuring changes in T1, measurement of the apparent 
diffusion coefficient (ADC), and detection of macromolecular contrast agent uptake, all of 
which showed early profound changes [19, 25]. For instance, [18F]FDG uptake was found to 
be significantly reduced immediately following NIR PIT, suggesting that this treatment 
modality causes rapid cytotoxicity [25]. However, in vivo imaging of cell necrosis and 
related hemodynamic changes have been lacking, but would potentially be useful for 
treatment monitoring.
Cell necrosis and EPR are considered hallmarks of NIR PIT. Biomarkers that can detect 
these endpoints would be useful in a clinical setting to monitor the response to NIR PIT. 
13C-labeled fumarate, a substrate for fumarate hydratase (FH), can be hyperpolarized for 
MRI and used to non-invasively image necrotic death [26, 27]. Fumarate is converted to 
malate by FH, which is an intracellular enzyme. Fumarate is cell-impermeable and remains 
unmodified in intact tissue. Upon the rapid necrotic cell death seen following NIR PIT, we 
hypothesized that FH would leak out and convert fumarate to malate in the extracellular 
milieu. Blood flow and blood oxygenation can also be monitored by T2*-weighted MRI and 
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photoacoustic imaging (PAI), as these methods are influenced by deoxyhemoglobin and 
oxyhemoglobin, respectively [28–30]. The current study evaluates these imaging techniques 
to monitor therapeutic responses to NIR PIT in vivo.
Materials and Methods
Animals, tumor model, and PIT
All animal experiments were performed in compliance with the Guide for the Care and Use 
of Laboratory Animal Resources (National Research Council, 2011) and were approved by 
the NCI Animal Care and Use Committee. Female athymic nude mice were supplied by the 
Frederick National Laboratory for Cancer Research (Frederick, MD). A431 and H520 cell 
lines were purchased from the American Type Culture Collection (Manassas, VA). A431 and 
H520 solid tumors were formed by injecting 2 × 106 cells and 5 × 106 cells, respectively, 
subcutaneously into the right hind legs of mice. The tumor volume was calculated by using 
the formula for a prolate ellipsoid: length × width × depth × ½. The growth of A431 tumors 
(n = 5 for both control groups and PIT-treated groups) was monitored from when the tumor 
volume was approximately 200 mm3 to a volume of 1500 mm3. Mice were treated with PIT 
once at day 4 after tumor cells injection. During MRI and PAI measurements, the mouse 
breathing rate was monitored with a pressure transducer (SA Instruments Inc.) and was 
maintained at 80 ± 10 breaths per minute. Core body temperature was also monitored with a 
nonmagnetic rectal temperature probe (FISO, Québec, Canada) and was maintained at 36 
± 1°C.
Panitumumab-IR700 (Pan-IR700) was prepared using previously described methods [11]. 
For the in vitro study, cells were incubated with 12.5 µg/mL Pan-IR700 for 30 min, washed 
with PBS three times, and then exposed to NIR light illumination with infrared NIR LED 
laser at a wavelength of 690 nm (5 J/cm2). The cells were then washed with PBS three times 
and evaluated by flow cytometry. For in vivo studies, 24 h prior to PIT treatment, tumor-
bearing mice were pretreated with 200 µg of Pan-IR700 (i.p.). For T2*-weighted MRI and 
PAI experiments, the NIR light was delivered using a fiberoptic cable coupled with an LED 
laser (36 J/cm2). For 13C MRI experiments and tumor growth experiments, the same LED 
laser was used (200 J/cm2).
In vivo fluorescence imaging studies
Both A431 and H520 tumors were studied after they reached volumes of approximately 300 
mm3. Fluorescence images of Pan-IR700 were obtained with a fluorescence camera 
(Carestream, Carestream Health, Inc., NY) using a 690 nm excitation and 750 nm emission 
filters 24 h after i.p. injection of 200 µg of Pan-IR700. The fluorescence images were then 
overlaid on X-ray images of each mouse. The scale of signal detection is indicated in Figure 
1B.
Flow cytometry analysis
The affinity of tumor cells for Pan-IR700 was assessed by incubating cells (5 × 106) with or 
without Pan-IR700 on ice for 1 h followed by three washings in Dulbecco’s PBS (DPBS) 
+ 1% fetal bovine serum (FBS). PIT-induced lipid peroxidation was assessed by incubating 
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PIT-treated cells with rabbit anti-4-hydroxy-2-nonenal (4-HNE) Michael Adducts polyclonal 
antibody for 30 min on ice (1:250; EMD Millipore, Billerica, MA), followed by three 
washings in DPBS + 1% FBS and incubation with Alexa Fluor-conjugated goat anti-rabbit 
secondary antibody (1:250; Thermo Fisher Scientific Inc., Waltham, MA) for 1 h on ice. 
Following staining, the cell fluorescence was measured by flow cytometry 
(FACSCALIBUR, BD Biosciences, San Jose, CA).
Histostaining
Tumor-bearing mice were euthanized, and tumor tissues were removed from mice. Tumor 
tissues were frozen in OTC compound (SAKURA) using ultracold ethanol. Frozen tumors 
were sectioned to 10 mm thick using a cryostat, and the sections were thaw-mounted on 
glass slides. After fixed with 4% paraformaldehyde, sections were stained with hematoxylin 
and eosin and mounted on permount for histological observation.
FH enzyme activity assay
A serum sample was obtained from untreated mice and from NIR PIT-treated mice 1, 3, 6, 
12, 24 h after treatment (n = 3 in each group) and FH activity was measured with Fumarase 
Specific Activity Assay Kit (Abcam, Cambridge, MA) in accordance with the 
manufacturer’s instruction manual.
MRI experiments for R2* mapping and hyperpolarized 13C spectroscopy
The MRI experiments were initiated when the tumors were approximately 200–300 mm3. 
For T2*, and R2* mapping study, multiple gradient echo magnetic resonance images were 
acquired on a 9.4 Tesla MRI scanner (Bruker Biospin, Billerica, MA). The repetition time 
(TR), echo time (TE), number of average, flip angle, slice thickness, and field of view (FOV) 
were set to 312.5 ms, 7 ms, 1, 30 °, 3.2 mm, and 32 × 64 pixels (16 mm × 32 mm), 
respectively. For R2* measurements, images with multiple TE values (2, 7, 12, 17 and 22 ms 
for A431 tumors; and 2, 7, and 12 ms for H520 tumors) were used for calculation of T2* and 
R2* mapping. For 13C study, [1-13C] pyruvic acid (30 mL) or [1,4-13C2] fumaric acid (2.5 M 
in 30 mL deuterated DMSO), containing 15 mM Oxo63 and 2.5 mmol/L gadolinium chelate 
ProHance (Bracco Diagnostics, Monroe Township, NJ), was hyperpolarized using the 
Hypersense DNP polarizer (Oxford Instruments, Abingdon, UK) as described previously 
[32]. After the polarization reached 80% of the plateau value, the hyperpolarized sample was 
rapidly dissolved in 4.5 mL of a superheated alkaline buffer that consisted of 40 mmol/L 
HEPES, NaOH, and 100 mg/L EDTA. A hyperpolarized [1-13C] pyruvate or [1,4-13C2] 
fumarate solution (96 mmol/L and 16.7 mmol/L, respectively) was rapidly injected 
intravenously through a catheter placed in the tail vein of the mouse (12 mL/g body weight). 
The dynamic spectrum was taken from a 3 Tesla dedicated MR Solutions animal scanner 
(MR SOLUTIONS Ltd., Boston, MA) using a 17-mm home-built 13C solenoid coil placed 
inside of a saddle coil for 1H. The right leg with tumor implant was placed in the middle of 
the dual coil for data acquisition. During the scan, mice were anesthetized using isoflurane 
(1.5–2.5 %). Respiration was continuously monitored to ensure the animal well- being and 
and data reproducibility. Both 1H and 13C are tuned and matched and anatomical image was 
taken after shimed on proton. 13C spectra for [1-13C] pyruvate injection were acquired every 
1 sec for 240 sec from the whole leg including each tumor (n = 4 for control and n = 3 for 
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irradiated group). 13C spectra following hyperpolarized [1,4-13C2] fumarate injection were 
acquired for 180 sec in the same manner (n = 3 for control and n = 4 for irradiated group). 
The repetition time, spectral width, flip angle, and number of average were 1000 ms, 3300 
Hz, 10 °, and 1, respectively.
Photoacoustic imaging experiments
Tumors were imaged with the VisualSonics Vevo®LAZR System (FUJIFILM VisualSonics 
Inc., Canada) using a 21-MHz linear array transducer system (central frequency) integrated 
with a tunable nanosecond pulsed laser. The system was calibrated by the manufacturer 
before initiating data acquisition. Mice were anesthetized with isoflurane (1.5–2.5%) and 
raspiration and temperature were continuously monitored in the same manner as MR studies. 
The tumor area in the sagittal plane of the leg was determined manually from concurrently 
acquired ultrasound images. In this study, the experiments were performed on a fixed plane 
depicting the middle of the tumor in order to achieve better temporal resolution. For O2 
status assessments, photoacoustic images in the tumor area were collected with OxyHemo-
Mode (wavelength 750nm/850nm) every 1 sec for 10 min. Oxygen saturation of hemoglobin 
(sO2) and total hemoglobin values in the tumor area were calculated using OxyZatet™ tool 
based on a previously reported and tested algorithm [31]. For a noise control, threshold of 
total hemoglobin in relation to the maximum possibly leval was set to 20% for all 
experiments as this was found to be empirically reasonable value. Values below the 
threshold was discarded and appear black in all images.
Data analysis
MRI data were analyzed using MATLAB (MathWorks), ImageJ 1.49v (NIH), and Paravision 
5.1 (Bruker). R2* maps were derived by linear regression of log(MR signal intensity) for 
each pixel. Statistical analyses were carried out using R statistical software (https://
www.rproject.org/). Statistical significance was considered to be at the P<0.05 level. All 
results are expressed as mean ± standard deviation. Welch’s t-test was performed to evaluate 
the statistical difference between the groups. A log-rank test was performed for Kaplan 
Meier survival curves.
Results
Affinity of Pan-IR700 for EGFR-expressing cells
Two cell lines were used in these experiments: A431, which is a highly EGFR-positive 
tumor cell line, and H520, which does not express EGFR and served as a negative control. 
Panitumumab is a fully humanized IgG2 mAb directed against EGFR while cetuximab is a 
chimeric (mouse/human) mAb. The evaluation of PIT efficacy of both panitumumab-IR700 
(Pan-IR700: panitumumab covalently linked with IR700) and cetuximub-IR700 was 
performed by Sato.et al [16]. In their study, Pan-IR700 showed higher treatment efficacy due 
to its lower hepatic catabolism. Thus, in this study, we used Pan-IR700 for the evaluation of 
PIT treatment efficacy.
The binding affinity of each cell line was assessed after incubation with Pan-IR700 (12.5 
µM) for 30 min on ice, followed by washing and flow cytometry (Figure 1A). There was no 
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difference in the cytometric profiles of the unexposed versus Pan-IR700-treated H520 cells 
(Figure 1A, top), whereas there was a considerable difference in the cytometric profiles of 
unexposed versus Pan-IR700-treated A431 cells (Figure 1A, bottom). In vivo xenografts of 
A431 and H520 cells showed marked differences in fluorescence after administration of 
Pan-IR700. Figure 1B shows the fluorescence optical image overlaid on the corresponding 
X-ray image taken from A431 and H520 tumor-bearing mice 24 h after pretreatment with 
Pan-IR700. High target accumulation of Pan-IR700 was shown in the A431 tumor 
xenografts, but not in the H520 tumor xenografts. These in vitro and in vivo binding studies 
confirm the strong binding affinity of the Pan-IR700 immunoconjugate for the EGFR-
expressing tumor cells.
Anti-tumor effects of NIR PIT
The cytotoxic effects of PIT using Pan-IR700 were tested in A431 and H520 cells in vitro 
using flow cytometry. Figures 2A, B (top row) show the histograms of forward scatter 
analysis, which is sensitive to the sizes of NIR PIT-treated (red) and untreated (black) cells. 
The results indicate that only the EGFR-expressing A431 cells showed morphological 
changes after NIR PIT, as indicated by a right shift. On the other hand, the H520 cells 
treated with NIR PIT under identical conditions had no observable effects. Figures 2C, D 
(bottom row) show the histograms of the same cells stained with 4-HNE antibody, which 
detects products formed via lipid peroxidation. These results suggest that only EGFR-
expressing cells were susceptible to NIR PIT-mediated cytotoxicity, resulting in oxidative 
membrane damage.
The in vivo effects of NIR PIT on A431 and H520 xenografts pretreated with Pan-IR700 
were assessed following exposure to a 690 nm LED laser (200 J/cm2). The A431 and H520 
tumor specimens were dissected from animals immediately after NIR PIT. Figure 3A shows 
the H&E stained tissue sections of both untreated and NIR PIT-treated A431 and H520 
tumors. While the untreated and NIR PIT-treated H520 cells showed no morphological 
differences, the A431 cells treated with NIR PIT showed cellular expansion and regions with 
cell membrane rupture (Figure 3A, arrow in right bottom panel). Tumor growth rates were 
also measured for A431 tumors with and without NIR PIT treatment, and the results are 
shown as tumor growth kinetics (Figure 3B) and Kaplan-Meier survival curves (Figure 3C). 
The results show that while the control (no Pan-IR700) mice and mice receiving only Pan-
IR700 showed no effects, the group that received Pan-IR700 and NIR PIT (200 J/cm2) (filled 
squares) showed significant alterations in tumor growth and statistically significantly 
prolonged survival (p = 0.001). For instance, at the level of 50% survival, the NIR PIT 
treatment group showed a 1.44-fold prolongation of survival time.
Hyperpolarized 13C MRI detecting treatment response after NIR PIT
Necrotic cell death can be directly and non-invasively monitored by hyperpolarized MRI 
using 13C-labeled fumarate as a reporter. Fumarate is cell impermeable and therefore does 
not get converted to malate by FH, which is strictly intracellular in intact cells. However, in 
necrotic cells FH is released into the tumor bed immediately after necrosis and can convert 
fumarate to malate (Figure 4A). This phenomenon can be imaged by 13C MRI following 
injection of hyperpolarized [1,4-13C2] fumarate into treated and untreated mice, an approach 
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which was successfully shown to report on necrotic cell death in tumor xenografts treated 
with etoposide or in acute kidney injury [26, 27, 33]. The balance between apoptosis and 
necrosis induced by PDT depends on the type and dosage of photosensitizer. However, in 
case of PIT, due to high affinity of Pan-IR700 with EGFR, high level of accumulation of 
Pan-IR700 to cellular membrane is achieved, leading to acute necrotic cell death induced by 
the strong oxidative damage to cellular membrane. In this study, non-localized 1D spectral 
signal from tumor implanted leg was acquired continuously for 180 seconds after 
hyperpolarized [1,4-13C2] fumarate injection and the conversion of fumarate to malate was 
quantitatively assessed. We examined untreated and NIR PIT-treated mice with 
hyperpolarized MRI following administration of fumarate 1 h after NIR PIT, and the results 
are shown in Figure 4B. The untreated mice with A431 tumors showed no evidence of 
conversion of fumarate to malate while NIR PIT-treated mice with A431 tumors showed 
detectable malate production (Figure 4B), supporting necrotic cell death as a mechanism in 
NIR PIT. The malate to fumarate ratio was significantly different only in NIR PIT-treated 
mice (p = 0.02 at 30 sec after injection) (Figure 4C). To examine the release profile of FH 
following NIR PIT as an indicator of necrotic cell death, serum activity of this enzyme were 
determined (Figure 4D). FH levels were observed to increase following NIR PIT, reaching a 
peak at 6 h after treatment (p = 0.004 versus no treatment). These results suggest that FH 
activity may be a useful surrogate marker to monitor NIR PIT efficacy.
Hyperpolarized MRI has also been used to monitor response in tumor xenografts after 
treatment with anti-proliferative therapies such as doxorubicin and ionizing radiation using 
[1-13C] pyruvate administration [34, 35]. Tumor cells in vitro and in vivo exhibit high levels 
of aerobic glycolysis, which reflects a metabolic shift involving the conversion of pyruvate 
to lactate to generate energy (the Warburg phenomenon) [36]. A reduction in the conversion 
of pyruvate to lactate after anti-proliferative treatment in tumors can be associated with DNA 
damage, depletion of the NAD(P)H coenzyme pool, loss of lactate dehydrogenase (LDH) 
activity, and decreased cellularity. However, the conversion of pyruvate to lactate depends on 
LDH that is both intra- and extracellular. Thus, it was anticipated that NIR PIT would have 
no effect on conversion of pyruvate to lactate. Hyperpolarized 13C-MRI studies in A431 
tumor xenografts monitoring the conversion of pyruvate to lactate in control (untreated) or 
NIR PIT-treated mice showed no significant difference (Figure 4E), suggesting that the cell 
death induced by NIR PIT is markedly different compared to DNA damaging 
chemotherapeutic agents or ionizing radiation. Figure 4A schematically summarizes the 
results obtained from 13C MRI using hyperpolarized fumarate and pyruvate to monitor 
necrotic or metabolic changes following NIR PIT in A431 xenografts.
Assessment of treatment response during NIR PIT by T2*-weighted MRI
In a recent study, Sano et al. demonstrated that super-enhanced permeability and retention 
was induced by NIR PIT in tumors [20, 37]. This PIT-induced effect in tumor vasculature 
was exploited to deliver increased doses of nano-encapsulated chemotherapeutics such as 
doxorubicin to achieve improved therapeutic effects. We conducted continuous T2*-
weighted MRI with multiple TE values in the EGFR-expressing A431 tumor xenografts and 
the control H520 tumors following NIR PIT plus pre-treatment with Pan-IR700 to evaluate 
the hemodynamic changes. A set of images with multiple TE values is used to obtain T2* 
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and R2* maps and these mapes are acquired continuously for 600 seconds. Figure 5A shows 
the experimental protocol with four groups of tumor-bearing mice in this experiment (NIR 
applied group and NIR applied after Pan-IR700 treatment group for both H520 tumor and 
A431 tumor). Pan-IR700 (200 µg) was administered for localization. After 24 h, 36 J/cm2 of 
NIR illumination (wavelength 690 nm) was applied to the surface of the tumor of all groups 
using a fiberoptic cable coupled with an LED laser setup during the MRI acquisition. T2*-
weighted scans were carried out prior to (0–2 minutes), during (2–5 minutes), and after (5–
10 minutes) NIR exposure. Figure 5B shows the anatomic image followed by representative 
maps of the percentage change in T2*-weighted signal intensity before (2 min), immediately 
after NIR exposure (5 min), and at recovery (10 min post NIR exposure) in the H520 tumor 
xenograft (top row) and the A431 xenograft (bottom row). Change in R2* in the tumor area 
was plotted for A431 and H520 tumor xenografts treated with NIR but without Pan-IR700 or 
administered with Pan-IR700 24 h prior to treatment (Figure 5C). R2* in the tumor area was 
plotted in this study because T2*-weighted signals can be affected by flow effects (T1 
contrast). The R2* plot for the NIR PIT-treated A431 group showed a sharp rise immediately 
after the start of NIR PIT, followed by a significant decrease, which suggests a biphasic 
deoxyhemoglobin level change (Figure 5C, bottom). The R2* plot for A431 tumors without 
Pan-IR700 pre-administration showed only a gradual increase during NIR exposure, 
followed by a gradual return to near-baseline. This change is suggestive of increased 
deoxyhemoglobin levels delivered to dilated blood vessel due to heating by NIR exposure. 
Compared to the A431 tumors, modest dynamic changes were observed in the R2* maps of 
the H520 tumors.
Assessment of treatment response during NIR PIT by photoacoustic imaging (PAI)
PAI provides a dynamic assessment of changes in oxyhemoglobin and total hemoglobin with 
an anatomic overlay in live organisms by spectral measurement of hemoglobin at 750 nm 
and 850 nm. For a better understanding of the physiological changes monitored by MRI, 
which were attributed to R2* changes in the NIR PIT experiments with A431 tumor 
xenografts, we conducted PAI in the A431 and H520 xenografts in mice treated with Pan-
IR700. Results from before, during, and after NIR exposure are shown in Figure 6. The 
experimental protocol used for these experiments was identical to that used for the MRI 
experiments (Figure 5A). The NIR light exposure conditions were also the same as for the 
MRI experiments. Figure 6A shows the anatomic image (B mode) followed by PAI before 
(0–2 min), immediately after NIR exposure (5 min), and at recovery (10 min post-NIR 
exposure) in representative H520 tumor xenografts (top row) and A431 xenografts (bottom 
row). The results from these images of the tumor region are quantified as oxygen saturation 
of hemoglobin (sO2) and total hemoglobin concentration and plotted in Figure 6B. Almost 
no change in sO2 and a weak increase in hemoglobin concentration were observed during 
the NIR PIT in H520 tumors. To the contrary, A431 tumors showed a rapid drop in sO2 
accompanied by a drop in total hemoglobin, suggesting a marked reduction in blood volume. 
These changes agree with the R2* changes, suggesting increased deoxyhemoglobin, a 
consequence of lower sO2. The weak but non-significant increase in total hemoglobin in 
H520 tumors may be a result of vasodilation caused by mild heating from light exposure. 
The abrupt drop in sO2 and total hemoglobin in A431 tumors treated with NIR PIT was in 
agreement with the drop in blood flow from previous studies [38].
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Discussion
Recently developed photo-immunoconjugates using IR700 rely on the hydrophilic nature of 
this fluorophore and its ability to conjugate to targeted antibodies without changing the 
pharmacokinetics of the native macromolecule [12, 39]. Proposed mechanisms of 
phototoxicity include direct photochemical damage as well as photo-oxidation [40]. 
Experimental data suggest that at low radiant flux, photocatalytic reactions that conserve the 
chromophore and generate reactive oxygen species (ROS) may underlie PIT’s effects [40]. 
At higher radiant flux, generally a characteristic of dye bleaching experiments [41], direct 
phototoxicity independent of O2 or ROS may play a dominant role [11]. Similarly, in co-
culture experiments, only targeted cells displayed cytotoxicity whereas adjacent untargeted 
cells with access to ROS were unaffected, suggesting that direct effects may have a 
significant contribution [42]. In this study, in vitro membrane damage following cell 
expansion was observed only in A431 cells by flowcytometric analysis (Figure 2B and 2D). 
In vivo studies of A431 cells using Pan-IR700 are described in previous reports. NIR light 
(wavelength 690 nm) exposure induces immediate cytotoxic effects and eventually leads to 
tumor shrinkage [24]. The IR700 covalently linked in the hydrophilic region of the antibody 
confers multiple modes of damage in the Pan-IR700 molecule, which can support direct 
photochemical damage as well as contributions from photo-oxidation reactions. In vitro and 
in vivo studies confirmed that cell surface receptors for panitumumab and light exposure are 
necessary to elicit membrane damage leading to cell death in vitro [42]. A recent study 
examined imaging biomarkers in tumors treated with NIR PIT using Pan-IR700 [19]. MRI 
1–2 h after PIT in tumor-bearing mice showed increased T2* with an accompanying 
decrease in ADC within treated tumors. These observations suggest that PIT induced tumor 
edema, which can increase T2* values, while membrane rupture followed by extrusion of 
cellular contents results in increasing tumor viscosity and decreased ADC values in the 
tumor microenvironment immediately after treatment. Additional imaging studies showed 
that NIR PIT in combination with Pan-IR700 results in enhanced permeability, vessel 
dilation, blood pooling, and reduced blood flow [18–20, 38]. Considering the temporal 
changes we observed in serum FH and our histology data, PIT exerts its effects immediately 
after the treatment but needs a few hours for FH to be released into the systemic circulation.
The conversion of hyperpolarized [1,4-13C2] fumarate to malate in NIR PIT-treated A431 
tumor xenografts strongly suggests necrosis as a mechanism of cell death. Serum fumarate 
levels showed a peak 6 h post-PIT. These results provide direct support to previous studies 
suggesting tumor necrosis as the major effect of NIR PIT. Attenuated conversion of [1-13C] 
pyruvate to lactate is an established biomarker of treatment response in tumors when using 
DNA damaging treatments such as ionizing radiation or chemotherapeutic drugs [34, 35] 
that lead to metabolic death. The lack of change in pyruvate to lactate conversion in our 
assays suggests that the cause of cell death after NIR PIT is not metabolic but rather 
necrotic,.
It has been previously demonstrated that NIR PIT causes marked increases in permeability 
and retention of macromolecules [20]. It is proposed that the perivascular tumor destruction 
caused by NIR PIT leads to vascular resistance and leakage of serum into the tumor [18, 43]. 
This effect can be observed for up to 8 h after NIR PIT. Marked MRI signal intensity 
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changes were seen in NIR PIT-treated A431 tumors, with an accompanying increase in R2* 
during light exposure, suggesting that PIT induces a rapid accumulation of 
deoxyhemoglobin which may be associated with oxygen consumption. The sustained 
decrease in R2* after light exposure is consistent with earlier results in which decreased 
blood flow after PIT was observed. The decrease in sO2 and a decrease in total hemoglobin 
in A431 tumors detected by PAI (and not seen in H520 tumors treated with NIR PIT) 
suggests that NIR PIT is accompanied initially by rapid oxygen consumption and/or rapid 
drop in blood flow.
In conclusion, our study shows that the therapeutic effects of NIR PIT with Pan IR700 in 
EGFR expressing tumors can be monitored by imaging techniques such as hyperpolarized 
13C MRI, BOLD MRI, and PAI. This study elucidated the early metabolic and 
hemodynamic changes induced by NIR PIT using several clinically applicable imaging 
techniques whose results were corroborated by sO2 measurements and total hemoglobin 
changes acquired from PAI. The results provide direct evidence of the comprehensive 
tumoricidal effects of NIR PIT, including necrotic cell death mediated by photo-oxidation 
processes and dramatic hemodynamic changes, which suggests a unique mechanism of 
cancer cell death compared to standard therapies.
Acknowledgments
This research was supported by the Intramural Research Program of the Center of Cancer Research, National 
Cancer Institute, National Institutes of Health.
References
1. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol. 1984; 
2:83–116. [PubMed: 6397270] 
2. Levy JG. Photodynamic therapy. Trends Biotechnol. 1995; 13(1):14–8. [PubMed: 7765800] 
3. Roberts WG, Hasan T. Tumor-secreted vascular permeability factor/vascular endothelial growth 
factor influences photosensitizer uptake. Cancer Res. 1993; 53:153–7. [PubMed: 8416739] 
4. Mitchell JB, McPherson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of 
hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells. Cancer Res. 1985; 
45:2008–11. [PubMed: 3157442] 
5. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO. Photodynamic therapy of 
cancer: an update. CA Cancer J Clin. 2011; 61:250–81. [PubMed: 21617154] 
6. Girotti AW. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and 
cytoprotective mechanisms. J Photochem Photobiol B. 2001; 63:103–13. [PubMed: 11684457] 
7. Kessel D. Death pathways associated with photodynamic therapy. Med Laser Appl. 2006; 21:219–
24. [PubMed: 19890442] 
8. Pogrebniak HW, Matthews W, Black C, Russo A, Mitchell JB, Smith P. Targetted phototherapy with 
sensitizer-monoclonal antibody conjugate and light. Surg Oncol. 1993; 2:31–42.
9. Oseroff AR, Ohuoha D, Hasan T, Bommer JC, Yarmush ML. Antibody-targeted photolysis: 
selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 
conjugates. Proc Natl Acad Sci U S A. 1986; 83:8744–8. [PubMed: 2877461] 
10. Oseroff AR, Ara G, Ohuoha D, Aprille J, Bommer JC, Yarmush ML. Strategies for selective cancer 
photochemotherapy: antibody-targeted and selective carcinoma cell photolysis. Photochem 
Photobiol. 1987; 46:83–96. [PubMed: 3615636] 
Kishimoto et al. Page 11
Free Radic Biol Med. Author manuscript; available in PMC 2019 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-
selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat 
Med. 2011; 17:1685–91. [PubMed: 22057348] 
12. Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H. Immediate in 
vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012; 
12:345. [PubMed: 22873679] 
13. Nakamura Y, Ohler ZW, Householder D, Nagaya T, Sato K, Okuyama S. Near Infrared 
Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor 
Receptor (EGFR)-expressing Lung Cancer. Mol Cancer Ther. 2017; 16:408–14. [PubMed: 
28151706] 
14. Nagaya T, Sato K, Harada T, Nakamura Y, Choyke PL, Kobayashi H. Near Infrared 
Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the 
Conjugate-Light Regimen. PLoS One. 2015; 10:e0136829. [PubMed: 26313651] 
15. Nakajima T, Sato K, Hanaoka H, Watanabe R, Harada T, Choyke PL. The effects of conjugate and 
light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer. 2014; 14:389. [PubMed: 
24885589] 
16. Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I. Photoimmunotherapy: 
comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor 
receptor. Mol Oncol. 2014; 8:620–32. [PubMed: 24508062] 
17. Watanabe R, Hanaoka H, Sato K, Nagaya T, Harada T, Mitsunaga M. Photoimmunotherapy 
targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? J 
Nucl Med. 2015; 56:140–4. [PubMed: 25500827] 
18. Kobayashi H, Choyke PL. Super enhanced permeability and retention (SUPR) effects in tumors 
following near infrared photoimmunotherapy. Nanoscale. 2016; 8:12504–9. [PubMed: 26443992] 
19. Nakamura Y, Bernardo M, Nagaya T, Sato K, Harada T, Choyke PL. MR imaging biomarkers for 
evaluating therapeutic effects shortly after near infrared photoimmunotherapy. Oncotarget. 2016; 
7:17254–64. [PubMed: 26885619] 
20. Sano K, Nakajima T, Choyke PL, Kobayashi H. Markedly enhanced permeability and retention 
effects induced by photo-immunotherapy of tumors. ACS Nano. 2013; 7:717–24. [PubMed: 
23214407] 
21. Ogawa M, Tomita Y, Nakamura Y, Lee MJ, Lee S, Tomita S. Immunogenic cancer cell death 
selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
Oncotarget. 2017; 8:10425–36. [PubMed: 28060726] 
22. Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke PL. Spatially selective depletion of tumor-
associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016; 
8:352ra110.
23. Ali T, Nakajima T, Sano K, Sato K;Choyke PL, Kobayashi H. Dynamic fluorescent imaging with 
indocyanine green for monitoring the therapeutic effects of photoimmunotherapy. Contrast Media 
Mol Imaging. 2014; 9:276–82. [PubMed: 24706611] 
24. Nakajima T, Sano K;Mitsunaga M, Choyke PL, Kobayashi H. Real-time monitoring of in vivo 
acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence 
lifetime imaging. Cancer Res. 2012; 72:4622–8. [PubMed: 22800710] 
25. Sano K, Mitsunaga M, Nakajima T, Choyke PL, Kobayashi H. Acute cytotoxic effects of 
photoimmunotherapy assessed by 18F-FDG PET. J Nucl Med. 2013; 54:770–5. [PubMed: 
23536226] 
26. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M. Production of 
hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and 
treatment response in tumors. Proc Natl Acad Sci U S A. 2009; 106:19801–6. [PubMed: 
19903889] 
27. Witney TH, Kettunen MI, Hu DE, Gallagher FA, Bohndiek SE, Napolitano R. Detecting treatment 
response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and 
[1,4-13C2]fumarate. Br J Cancer. 2010; 103:1400–6. [PubMed: 20924379] 
Kishimoto et al. Page 12
Free Radic Biol Med. Author manuscript; available in PMC 2019 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation 
dependent contrast (FLOOD) imaging of tumours. NMR Biomed. 2001; 14:497–506. [PubMed: 
11746943] 
29. Mallidi S, Luke GP, Emelianov S. Photoacoustic imaging in cancer detection, diagnosis, and 
treatment guidance. Trends Biotechnol. 2011; 29:213–21. [PubMed: 21324541] 
30. Taruttis A, van Dam GM, Ntziachristos V. Mesoscopic and macroscopic optoacoustic imaging of 
cancer. Cancer Res. 2015; 75:1548–59. [PubMed: 25836718] 
31. Laufer J, Delpy D, Elwell C, Beard P. Quantitative spatially resolved measurement of tissue 
chromophore concentrations using photoacoustic spectroscopy: application to the measurement of 
blood oxygenation and haemoglobin concentration. Phys Med Biol. 2007; 52:141–68. [PubMed: 
17183133] 
32. Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M. EPR oxygen iimaging and 
hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment 
response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med. 2013; 69:1443–50. 
[PubMed: 22692861] 
33. Nielsen PM, Eldirdiri A;Bertelsen LB;Jorgensen HS, Ardenkjaer-Larsen JH, Laustsen C. Fumarase 
activity: an in vivo and in vitro biomarker for acute kidney injury. Sci Rep. 2017; 7:40812. 
[PubMed: 28094329] 
34. Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD. Detecting response of 
rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic 
resonance spectroscopic imaging. Magn Reson Med. 2011; 65:557–63. [PubMed: 21264939] 
35. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J. Detecting tumor response to 
treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med. 
2007; 13:1382–7. [PubMed: 17965722] 
36. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of 
cancers. J Nucl Med. 2008; 49(Suppl 2):24S–42S. [PubMed: 18523064] 
37. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid 
tumors online by BOLD-contrast MRI. Nat Med. 2003; 9:1327–31. [PubMed: 14502284] 
38. Liang CP, Nakajima T, Watanabe R, Sato K, Choyke PL, Chen Y. Real-time monitoring of 
hemodynamic changes in tumor vessels during photoimmunotherapy using optical coherence 
tomography. J Biomed Opt. 2014; 19:98004. [PubMed: 25253195] 
39. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared theranostic 
photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. 
Bioconjug Chem. 2012; 23:604–9. [PubMed: 22369484] 
40. Kishimoto S, Bernardo M, Saito K, Koyasu S, Mitchell JB, Choyke PL. Evaluation of oxygen 
dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody 
conjugates. Free Radic Biol Med. 2015; 85:24–32. [PubMed: 25862414] 
41. Sato K, Watanabe R, Hanaoka H, Nakajima T, Choyke PL, Kobayashi H. Comparative 
effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. 
Oncotarget. 2016; 7:14324–35. [PubMed: 26885688] 
42. Sato K, Nakajima T, Choyke PL, Kobayashi H. Selective cell elimination in vitro and in vivo from 
tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv. 
2015; 5:25105–14. [PubMed: 25866624] 
43. Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug Delivery: Is the Enhanced 
Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjug Chem. 2016; 27:2225–
38. [PubMed: 27547843] 
Kishimoto et al. Page 13
Free Radic Biol Med. Author manuscript; available in PMC 2019 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
The mechanism of photoimmunotherapy relies on photo-oxidation.
Acute necrotic damage by photoimmunotherapy induces decreased blood flow.
13C MR spectroscopy with [1,4]-13C fumarate is useful for an early detection of 
therapeutic effect of photoimmunotherapy.
Serum fumarase can serve as a treatment response biomarker for photoimmunotherapy.
Photoacoustic imaging provides information of real-time hemodynamic change during 
photoimmunotherapy.
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Figure 1. 
Target accumulation of Pan-IR700 in A431 and H520 cells in vitro and in vivo. (A) A flow 
cytometry analysis for Pan-IR700 affinity for A431 (top) and H520 (bottom) cells (black 
line: untreated, red line: Pan-IR700-treated). (B) Nude mice implanted with H520 tumors 
(left) and A431 tumors (right) in the right hind leg were injected with Pan-IR700 24 h prior 
to fluorescence imaging. Both mice were imaged in the same frame and fluorescence and X-
ray modes were simply co-registered.
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Figure 2. 
Flow cytometry analysis for oxidative stress. (A–B) Forward scatter histograms. (C–D) 4-
HNE staining histograms. H520 cells (A and C) and A431 cells (B and D) treated with 4-
HNE antibody labeled dye were examined by flow cytometry (black line: untreated, red line: 
NIR PIT-treated). A and B indicate expanded cell size only in NIR PIT-treated A431 cells. C 
and D indicate that oxidative stress marker 4-HNE is stained only in NIR PIT-treated A431 
cells.
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Figure 3. 
In vivo tumoricidal effects of NIR PIT. (A) Morphological change in NIR PIT treated tumor 
cells. Hematoxylin and eosin staining for untreated and NIR PIT treated H520 tumor cells 
(top row) and untreated and NIR PIT-treated A431 tumor cells (bottom row). Membrane 
rupture is indicated by the black arrow. (B) Tumor growth plot for A431 tumors. Closed 
squares: Pan-IR700 with NIR PIT (n = 5), open squares: Pan-IR700 only (n = 5), and open 
circles: no treatment (n = 5). (C) Kaplan-Meier survival curve. Solid line: no treatment 
(control), dashed line: Pan-IR700, and dotted line: Pan-IR700 with NIR PIT. A statistically 
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significant difference between the control group and the NIR PIT group was observed by a 
log-rank test (p = 0.001).
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Figure 4. 
Hyperpolarization 13C MRI analysis to detect the tumoricidal effects of NIR PIT. (A) 
Proposed scheme of enzymatic reactions in tumor cells before and after NIR PIT. (B) 
Dynamic spectra of untreated A431 tumors (top, n = 3) and NIR PIT-treated A431 tumors 
(bottom, n = 4) after hyperpolarized [1,4-13C2] fumarate injection. A malate signal is 
detected only in NIR PIT-treated tumors. Scatter plots for both fumarate and malate signals 
are shown at right. (C) Plot of malate to fumarate ratio for untreated (black) and NIR PIT-
treated (red) A431 tumor cells. (D) Trend of serum FH activity after NIR PIT in A431 tumor 
cells, normalized to the untreated control group (n = 3). (E) Dynamic spectra of untreated 
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(top, n = 4) and NIR PIT-treated (bottom, n = 3) A431 tumors after [1-13C] pyruvate 
injection. Scatter plots for the pyruvate and lactate signals (middle) and the lactate to 
pyruvate ratio (right) are shown.
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Figure 5. 
Change in T2*-weighted sequential MRI and R2* during and after NIR PIT. (A) Design of 
the MRI experiment. (B) Anatomical image and temporal change in T2*-weighted images 
for NIR-treated (top rows, n = 6) and Pan-IR700/NIR PIT-treated (bottom rows, n = 5) 
tumors. Representative images are shown for both H520 (top panel) and A431 (bottom 
panel) tumors. T2*-weighted images are processed to show the percentage changes (−20% to 
+20%) from the average image acquired in the baseline scan (0–2 min). (C) Plot of change 
in R2* in tumor area over time. NIR PIT affected the R2* in EGFR-targeted A431 tumor 
cells but not non-targeted H520 cells.
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Figure 6. 
Changes in sO2 and total hemoglobin during and after NIR PIT. (A) Anatomical image (B 
mode) and temporal change in sO2 for NIR PIT-treated H520 (top row, n = 4) and A431 
(bottom row, n = 3) tumors. A darkened color map was observed in A431 tumors after NIR 
PIT treatment. (B) Plots of sO2 (left) and total hemoglobin (right) in A431 (red) and H520 
(black) tumors. Both sO2 and total hemoglobin values dropped in A431 tumors during NIR 
PIT, while non-significant changes were observed in H520 tumors.
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